News & Media

AmacaThera Announces Close of Oversubscribed Series A Financing

   Press Release

Clinical trials set to begin on their proprietary drug delivery platform addresses key problem in sustained therapeutic delivery and is applicable to numerous disease indications and therapeutic modalities​.Read more

SCIENCE hydrogels ROBERTA BAKER molly schoichet web

Professor Molly Shoichet awarded the Gerzhard Herzberg Canada Gold Medal

   Media Coverage

Biomedical engineer’s novel hydrogel designs useful for regenerative medicine.Read more

AmacaThera Secures Funding to Initiate Phase I Trial of Non-Opioid Pain Control Therapeutic

   Press Release

AmacaThera, a Toronto-based company commercializing hydrogel-based drug delivery platforms, has already raised $3.25 million (CAD) in seed financing from Sprout BioVentures, Viva Biotech, and Grey Sky Venture Partners.Read more

Ontario Names Molly Shoichet the Province's First Chief Scientist

   Press Release

Shoichet Will Help Accelerate Scientific Innovation and Advance Science in Government Decision-Making.Read more

Amacathera Logo

AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.

Contact Us

416-360-2094
MaRS Centre, West Tower,
661 University Ave Suite 1300,
Toronto, ON M5G 0B7

[email protected]